Invitrogen™ MIG/CXCL9 Human ELISA Kit

Descripción

The Human MIG/CXCL9 (Hu MIG) ELISA quantitates Hu MIG in human serum, plasma, or cell culture medium. The assay will exclusively recognize both natural and recombinant Hu MIG. Principle of the method The Human MIG solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples, standards, or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the addition of the second (detector) antibody, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of target present in the original specimen. Rigorous validation Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.

MIG (monokine induced by interferon gamma), or CXCL9, belongs to the subfamily of the CXC chemokines. The main function of this soluble protein is the recruitment of leukocytes to sites of infection and inflammation. MIG binds to a receptor which is selectively expressed in activated T lymphocytes and therefore is a critical mediator of T-lymphocyte migration in T-cell dependent immune responses. This displays antiviral activity. Like IP-10 it binds to chemokine receptor CXCR3 in Th1 immune reactions and exhibits inhibitory functions in neovascularization, is an inhibitor for hematopoietic progenitor cells and shows anti-tumor effects. Furthermore there are indications that MIG plays an important role in mediating cell recruitment and activation necessary for inflammation and the repair of tissue damage e.g. in liver diseases.